The coronary stents market has become a vital segment within the broader cardiovascular healthcare industry. With the rising prevalence of coronary artery diseases and growing awareness of ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of ...

In patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), stenting demonstrated improved ...

Understanding calcified coronary artery disease, its risk factors, symptoms, diagnosis, treatment, and prevention for a ...

A major international study has found that heart patients, particularly seniors, may benefit more from newer blood-thinning ...

University of Iowa Health Care has become the first in Iowa to offer drug-coated balloon therapy for patients with blockages ...

[2,11,25,42] However, the main limitation of durable polymers are that they remain exposed for long periods of time to the coronary artery ... biodegradable polymer stents have been developed ...

Innovative, dual-layer micromesh, closed-cell stent with the flexibility of an open-cell stent for maximizing clinical outcomes in carotid artery stenting procedures - ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of ...

4D-ACS trial investigators found that after placement of a drug-coated stent (DCS), the incidence of net adverse clinical ...

[32] This multicenter trial randomized 2300 patients with symptomatic coronary artery disease (CAD) to receive the Resolute stent (1150) or EES (1150). At the 12-month follow-up, ZES was found to ...